Predictors of mortality in hospital survivors with type 2 diabetes mellitus and acute coronary syndromes

Stefano Savonitto, Nuccia Morici, Anna Nozza, Francesco Cosentino, Pasquale Perrone Filardi, Ernesto Murena, Giorgio Morocutti, Marco Ferri, Claudio Cavallini, Marinus J.C. Eijkemans, Barbara E. Stähli, Ilse C. Schrieks, Tadashi Toyama, H. J. Lambers Heerspink, Klas Malmberg, Gregory G. Schwartz, A. Michael Lincoff, Lars Ryden, Jean Claude Tardif, Diederick E. Grobbee

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Aim: To define the predictors of long-term mortality in patients with type 2 diabetes mellitus and recent acute coronary syndrome. Methods and results: A total of 7226 patients from a randomized trial, testing the effect on cardiovascular outcomes of the dual peroxisome proliferator–activated receptor agonist aleglitazar in patients with type 2 diabetes mellitus and recent acute coronary syndrome (AleCardio trial), were analysed. Median follow-up was 2 years. The independent mortality predictors were defined using Cox regression analysis. The predictive information provided by each variable was calculated as percent of total chi-square of the model. All-cause mortality was 4.0%, with cardiovascular death contributing for 73% of mortality. The mortality prediction model included N-terminal proB-type natriuretic peptide (adjusted hazard ratio = 1.68; 95% confidence interval = 1.51–1.88; 27% of prediction), lack of coronary revascularization (hazard ratio = 2.28; 95% confidence interval = 1.77–2.93; 18% of prediction), age (hazard ratio = 1.04; 95% confidence interval = 1.02–1.05; 15% of prediction), heart rate (hazard ratio = 1.02; 95% confidence interval = 1.01–1.03; 10% of prediction), glycated haemoglobin (hazard ratio = 1.11; 95% confidence interval = 1.03–1.19; 8% of prediction), haemoglobin (hazard ratio = 1.01; 95% confidence interval = 1.00–1.02; 8% of prediction), prior coronary artery bypass (hazard ratio = 1.61; 95% confidence interval = 1.11–2.32; 7% of prediction) and prior myocardial infarction (hazard ratio = 1.40; 95% confidence interval = 1.05–1.87; 6% of prediction). Conclusion: In patients with type 2 diabetes mellitus and recent acute coronary syndrome, mortality prediction is largely dominated by markers of cardiac, rather than metabolic, dysfunction.

Original languageEnglish
Pages (from-to)14-23
Number of pages10
JournalDiabetes and Vascular Disease Research
Volume15
Issue number1
DOIs
Publication statusPublished - Jan 1 2018
Externally publishedYes

Fingerprint

Acute Coronary Syndrome
Hospital Mortality
Type 2 Diabetes Mellitus
Survivors
Confidence Intervals
Mortality
Natriuretic Peptides
Peroxisomes
Glycosylated Hemoglobin A
Coronary Artery Bypass
Hemoglobins
Heart Rate
Myocardial Infarction
Regression Analysis

Keywords

  • Acute coronary syndromes
  • diabetes mellitus
  • mortality

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Cardiology and Cardiovascular Medicine

Cite this

Savonitto, S., Morici, N., Nozza, A., Cosentino, F., Perrone Filardi, P., Murena, E., ... Grobbee, D. E. (2018). Predictors of mortality in hospital survivors with type 2 diabetes mellitus and acute coronary syndromes. Diabetes and Vascular Disease Research, 15(1), 14-23. https://doi.org/10.1177/1479164117735493

Predictors of mortality in hospital survivors with type 2 diabetes mellitus and acute coronary syndromes. / Savonitto, Stefano; Morici, Nuccia; Nozza, Anna; Cosentino, Francesco; Perrone Filardi, Pasquale; Murena, Ernesto; Morocutti, Giorgio; Ferri, Marco; Cavallini, Claudio; Eijkemans, Marinus J.C.; Stähli, Barbara E.; Schrieks, Ilse C.; Toyama, Tadashi; Lambers Heerspink, H. J.; Malmberg, Klas; Schwartz, Gregory G.; Lincoff, A. Michael; Ryden, Lars; Tardif, Jean Claude; Grobbee, Diederick E.

In: Diabetes and Vascular Disease Research, Vol. 15, No. 1, 01.01.2018, p. 14-23.

Research output: Contribution to journalArticle

Savonitto, S, Morici, N, Nozza, A, Cosentino, F, Perrone Filardi, P, Murena, E, Morocutti, G, Ferri, M, Cavallini, C, Eijkemans, MJC, Stähli, BE, Schrieks, IC, Toyama, T, Lambers Heerspink, HJ, Malmberg, K, Schwartz, GG, Lincoff, AM, Ryden, L, Tardif, JC & Grobbee, DE 2018, 'Predictors of mortality in hospital survivors with type 2 diabetes mellitus and acute coronary syndromes', Diabetes and Vascular Disease Research, vol. 15, no. 1, pp. 14-23. https://doi.org/10.1177/1479164117735493
Savonitto, Stefano ; Morici, Nuccia ; Nozza, Anna ; Cosentino, Francesco ; Perrone Filardi, Pasquale ; Murena, Ernesto ; Morocutti, Giorgio ; Ferri, Marco ; Cavallini, Claudio ; Eijkemans, Marinus J.C. ; Stähli, Barbara E. ; Schrieks, Ilse C. ; Toyama, Tadashi ; Lambers Heerspink, H. J. ; Malmberg, Klas ; Schwartz, Gregory G. ; Lincoff, A. Michael ; Ryden, Lars ; Tardif, Jean Claude ; Grobbee, Diederick E. / Predictors of mortality in hospital survivors with type 2 diabetes mellitus and acute coronary syndromes. In: Diabetes and Vascular Disease Research. 2018 ; Vol. 15, No. 1. pp. 14-23.
@article{80ff34c514514fb6986eaab0984077f3,
title = "Predictors of mortality in hospital survivors with type 2 diabetes mellitus and acute coronary syndromes",
abstract = "Aim: To define the predictors of long-term mortality in patients with type 2 diabetes mellitus and recent acute coronary syndrome. Methods and results: A total of 7226 patients from a randomized trial, testing the effect on cardiovascular outcomes of the dual peroxisome proliferator–activated receptor agonist aleglitazar in patients with type 2 diabetes mellitus and recent acute coronary syndrome (AleCardio trial), were analysed. Median follow-up was 2 years. The independent mortality predictors were defined using Cox regression analysis. The predictive information provided by each variable was calculated as percent of total chi-square of the model. All-cause mortality was 4.0{\%}, with cardiovascular death contributing for 73{\%} of mortality. The mortality prediction model included N-terminal proB-type natriuretic peptide (adjusted hazard ratio = 1.68; 95{\%} confidence interval = 1.51–1.88; 27{\%} of prediction), lack of coronary revascularization (hazard ratio = 2.28; 95{\%} confidence interval = 1.77–2.93; 18{\%} of prediction), age (hazard ratio = 1.04; 95{\%} confidence interval = 1.02–1.05; 15{\%} of prediction), heart rate (hazard ratio = 1.02; 95{\%} confidence interval = 1.01–1.03; 10{\%} of prediction), glycated haemoglobin (hazard ratio = 1.11; 95{\%} confidence interval = 1.03–1.19; 8{\%} of prediction), haemoglobin (hazard ratio = 1.01; 95{\%} confidence interval = 1.00–1.02; 8{\%} of prediction), prior coronary artery bypass (hazard ratio = 1.61; 95{\%} confidence interval = 1.11–2.32; 7{\%} of prediction) and prior myocardial infarction (hazard ratio = 1.40; 95{\%} confidence interval = 1.05–1.87; 6{\%} of prediction). Conclusion: In patients with type 2 diabetes mellitus and recent acute coronary syndrome, mortality prediction is largely dominated by markers of cardiac, rather than metabolic, dysfunction.",
keywords = "Acute coronary syndromes, diabetes mellitus, mortality",
author = "Stefano Savonitto and Nuccia Morici and Anna Nozza and Francesco Cosentino and {Perrone Filardi}, Pasquale and Ernesto Murena and Giorgio Morocutti and Marco Ferri and Claudio Cavallini and Eijkemans, {Marinus J.C.} and St{\"a}hli, {Barbara E.} and Schrieks, {Ilse C.} and Tadashi Toyama and {Lambers Heerspink}, {H. J.} and Klas Malmberg and Schwartz, {Gregory G.} and Lincoff, {A. Michael} and Lars Ryden and Tardif, {Jean Claude} and Grobbee, {Diederick E.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1177/1479164117735493",
language = "English",
volume = "15",
pages = "14--23",
journal = "Diabetes and Vascular Disease Research",
issn = "1479-1641",
publisher = "SAGE Publications Ltd",
number = "1",

}

TY - JOUR

T1 - Predictors of mortality in hospital survivors with type 2 diabetes mellitus and acute coronary syndromes

AU - Savonitto, Stefano

AU - Morici, Nuccia

AU - Nozza, Anna

AU - Cosentino, Francesco

AU - Perrone Filardi, Pasquale

AU - Murena, Ernesto

AU - Morocutti, Giorgio

AU - Ferri, Marco

AU - Cavallini, Claudio

AU - Eijkemans, Marinus J.C.

AU - Stähli, Barbara E.

AU - Schrieks, Ilse C.

AU - Toyama, Tadashi

AU - Lambers Heerspink, H. J.

AU - Malmberg, Klas

AU - Schwartz, Gregory G.

AU - Lincoff, A. Michael

AU - Ryden, Lars

AU - Tardif, Jean Claude

AU - Grobbee, Diederick E.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Aim: To define the predictors of long-term mortality in patients with type 2 diabetes mellitus and recent acute coronary syndrome. Methods and results: A total of 7226 patients from a randomized trial, testing the effect on cardiovascular outcomes of the dual peroxisome proliferator–activated receptor agonist aleglitazar in patients with type 2 diabetes mellitus and recent acute coronary syndrome (AleCardio trial), were analysed. Median follow-up was 2 years. The independent mortality predictors were defined using Cox regression analysis. The predictive information provided by each variable was calculated as percent of total chi-square of the model. All-cause mortality was 4.0%, with cardiovascular death contributing for 73% of mortality. The mortality prediction model included N-terminal proB-type natriuretic peptide (adjusted hazard ratio = 1.68; 95% confidence interval = 1.51–1.88; 27% of prediction), lack of coronary revascularization (hazard ratio = 2.28; 95% confidence interval = 1.77–2.93; 18% of prediction), age (hazard ratio = 1.04; 95% confidence interval = 1.02–1.05; 15% of prediction), heart rate (hazard ratio = 1.02; 95% confidence interval = 1.01–1.03; 10% of prediction), glycated haemoglobin (hazard ratio = 1.11; 95% confidence interval = 1.03–1.19; 8% of prediction), haemoglobin (hazard ratio = 1.01; 95% confidence interval = 1.00–1.02; 8% of prediction), prior coronary artery bypass (hazard ratio = 1.61; 95% confidence interval = 1.11–2.32; 7% of prediction) and prior myocardial infarction (hazard ratio = 1.40; 95% confidence interval = 1.05–1.87; 6% of prediction). Conclusion: In patients with type 2 diabetes mellitus and recent acute coronary syndrome, mortality prediction is largely dominated by markers of cardiac, rather than metabolic, dysfunction.

AB - Aim: To define the predictors of long-term mortality in patients with type 2 diabetes mellitus and recent acute coronary syndrome. Methods and results: A total of 7226 patients from a randomized trial, testing the effect on cardiovascular outcomes of the dual peroxisome proliferator–activated receptor agonist aleglitazar in patients with type 2 diabetes mellitus and recent acute coronary syndrome (AleCardio trial), were analysed. Median follow-up was 2 years. The independent mortality predictors were defined using Cox regression analysis. The predictive information provided by each variable was calculated as percent of total chi-square of the model. All-cause mortality was 4.0%, with cardiovascular death contributing for 73% of mortality. The mortality prediction model included N-terminal proB-type natriuretic peptide (adjusted hazard ratio = 1.68; 95% confidence interval = 1.51–1.88; 27% of prediction), lack of coronary revascularization (hazard ratio = 2.28; 95% confidence interval = 1.77–2.93; 18% of prediction), age (hazard ratio = 1.04; 95% confidence interval = 1.02–1.05; 15% of prediction), heart rate (hazard ratio = 1.02; 95% confidence interval = 1.01–1.03; 10% of prediction), glycated haemoglobin (hazard ratio = 1.11; 95% confidence interval = 1.03–1.19; 8% of prediction), haemoglobin (hazard ratio = 1.01; 95% confidence interval = 1.00–1.02; 8% of prediction), prior coronary artery bypass (hazard ratio = 1.61; 95% confidence interval = 1.11–2.32; 7% of prediction) and prior myocardial infarction (hazard ratio = 1.40; 95% confidence interval = 1.05–1.87; 6% of prediction). Conclusion: In patients with type 2 diabetes mellitus and recent acute coronary syndrome, mortality prediction is largely dominated by markers of cardiac, rather than metabolic, dysfunction.

KW - Acute coronary syndromes

KW - diabetes mellitus

KW - mortality

UR - http://www.scopus.com/inward/record.url?scp=85038591294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038591294&partnerID=8YFLogxK

U2 - 10.1177/1479164117735493

DO - 10.1177/1479164117735493

M3 - Article

C2 - 29052439

AN - SCOPUS:85038591294

VL - 15

SP - 14

EP - 23

JO - Diabetes and Vascular Disease Research

JF - Diabetes and Vascular Disease Research

SN - 1479-1641

IS - 1

ER -